Table 5.

Joint effect of NAT2 acetylation genotype and history of diabetes in modifying risk of pancreatic cancer

NAT2 acetylation genotypeHistory of diabetesPatients (n = 526)
Controls (n = 564)
OR* (95% CI)PtrendPinteraction
n (%)n (%)
All study participants
    All other;No285 (54.2)335 (59.4)1.00
    *6A/*5 + *6A/*6 + *6A/*7No134 (25.5)178 (31.6)0.90 (0.68-1.19)
    All other;Yes64 (12.2)36 (6.4)2.04 (1.31-3.21)
    *6A/*5 + *6A/*6 + *6A/*7Yes43 (8.1)15 (2.6)3.51 (1.90-6.50)<0.0010.12
    Rapid/intermediateNo196 (36.3)215 (38.1)1.00
    SlowNo228 (43.4)298 (52.8)0.87 (0.67-1.14)
    Rapid/intermediateYes35 (6.6)23 (4.1)1.53 (0.86-2.73)
    SlowYes72 (13.7)28 (5.0)3.10 (1.90-5.05)<0.0010.07
Never smokers
    All othersNo114 (52.8)161 (57.3)1.00
    *6A/*5 + *6A/*6 + *6A/*7No61 (28.2)97 (34.5)0.92 (0.61-1.40)
    All othersYes27 (12.5)15 (5.3)2.38 (1.19-4.75)
    *6A/*5 + *6A/*6 + *6A/*7Yes14 (6.5)8 (2.8)2.66 (1.07-6.59)0.010.88
    Rapid/intermediateNo85 (39.4)101 (35.9)1.00
    SlowNo90 (41.7)157 (55.9)0.71 (0.48-1.06)
    Rapid/intermediateYes14 (6.5)7 (2.4)2.14 (0.81-5.68)
    SlowYes27 (12.5)16 (5.7)2.07 (1.03-3.99)0.060.72
Ever smokers
    All othersNo171 (55.2)171 (61.0)1.00
    *6A/*5 + *6A/*6 + *6A/*7No73 (23.6)81 (29.0)0.88 (0.59-1.30)
    All othersYes37 (11.9)21 (7.5)1.89 (1.04-3.42)
    *6A/*5 + *6A/*6 + *6A/*7Yes29 (9.3)7 (2.5)4.59 (1.94-10.88)<0.0010.07
    Rapid/intermediateNo106 (34.2)112 (40.0)1.00
    SlowNo138 (44.5)140 (50.0)1.05 (0.73-1.52)
    Rapid/intermediateYes21 (6.8)16 (5.7)1.42 (0.68-2.95)
    SlowYes45 (14.5)12 (4.3)4.65 (2.29-9.42)<0.0010.04
  • * OR (95% CI) adjusted for age, sex, and NAT1 genotype (rapid versus others). Smoking pack-year (light versus heavy) was additionally adjusted for ever smokers. Smoking pack-year (never, light, and heavy) was additionally adjusted for all participants.

  • P value for the trend test. Score test was used to test the linear trend by treating interaction term as the continuous variable.

  • P value for the likelihood ratio test.